Komori
Immuno-Biological Laboratories (4570) · PolicyAdvanced

Enhancing transparency, expediting decision-making, and strengthening internal controls

First written in FY2016. 5 of 10 entries say "Advanced", first in 2026-03-17. Latest entry: FY2026.

10entries
11years
5from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20252016: 120162017: 120172018: 020182019: 120192020: 020202021: 020212022: 020222023: 020232024: 020242025: 120252026: 62026
Same theme, other companies
Transition to a Company with an Audit and Supervisory CommitteeA theme 782 companies write about · 0 as a headwind · 791 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 791 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「At the 44th Annual General Meeting of Shareholders held on 25 June 2026, a proposal to amend the Articles of Incorporation to transition to a company with an Audit and Supervisory Committee was approved. Accordingly, the Company changed from a company with a Board of Company Auditors to a company with an Audit and Supervisory Committee on the same date. Through this transition, the Company is strengthening the Board of Directors' oversight functions, further enhancing and reinforcing corporate governance, and pursuing sustained growth in corporate value.」

    The Company changed from a company with a Board of Company Auditors to a company with an Audit and Supervisory Committee and established an Audit and Supervisory Committee comprising 3 outside directors. It moved to a structure designed to strengthen the Board of Directors' oversight functions and accelerate decision-making and execution.
  2. FY2025RestatedAnnual report

    「To establish a highly transparent management system, the Company plans to improve management efficiency and accelerate decision-making in response to rapid changes in the business environment, while developing its internal control organisation and enhancing its management oversight functions.」

    The Company continues to pursue a governance policy that emphasises transparency, swift decision-making, internal controls, and management oversight.
  3. FY2019RestatedAnnual report

    「To establish a highly transparent management system, the Company plans to improve management efficiency and accelerate decision-making in response to rapid changes in the business environment, while developing its internal control organisation and enhancing its management oversight functions.」

    The Company has reiterated its governance policy of emphasising transparency, swift decision-making, internal controls, and management oversight.
  4. FY2017RestatedAnnual report

    「To establish a highly transparent management system, the Company plans to improve management efficiency and accelerate decision-making in response to rapid changes in the business environment, while developing its internal control organisation and enhancing its management oversight functions.」

    The Company has reiterated its policy of emphasising transparency, swift decision-making, internal controls, and management oversight.
  5. FY2016First statedAnnual report

    「To establish a highly transparent management system, the Company plans to improve management efficiency and accelerate decision-making in response to rapid changes in the business environment, while developing its internal control organisation and enhancing its management oversight functions.」

    Against a backdrop of an expanding company and broader stakeholder base, the Company places emphasis on transparency, swift decision-making, internal controls, and oversight functions.
Moved together

"Research Reagents and Contract Services Based on Antibody-Generation Technology" moved the same way as this thread, in the same document, in 2 of its 10 moves.

222222★123456
  1. ★This thread
  2. 1Research Reagents and Contract Services Based on Antibody-Generation Technology2×
  3. 2Expansion of Overseas Sales Activities2×
  4. 3Improving Profitability Through a Change in the Sales Policy for the Diagnostics and Reagents Business2×
  5. 4Securing Earnings and Focusing Management Resources2×
  6. 5Consistent, Stable Dividends and Reinvestment in Research and Development2×
  7. 6Narrowing Operating Losses and Continued Losses2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Immuno-Biological Laboratories yet. It last moved in the Other Disclosures of 2026-06-23: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Enhancing transparency, expediting decision-making, and strengthening internal controls | Immuno-Biological Laboratories Co.,Ltd. (4570) | Komori